Lorena Musco

Lorena Musco

Auto-generated profile, based on publicly available information

Lorena Musco

Centro di Riferimento Oncologico di Aviano (CRO)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Cancer Research
Verified
Journal Article
Closed access
PDF file
FCFrancesca Citron
Francesca Citron
ISIlenia Segatto
Ilenia Segatto
GVGian Luca Rampioni Vinciguerra
Gian Luca Rampioni Vinciguerra
LMLorena Musco
Lorena Musco
FRFrancesca Russo
Francesca Russo
BBBarbara Belletti
Barbara Belletti
MiR-223 is an anti-inflammatory miRNA that in cancer acts either as an oncosuppressor or oncopromoter, in a context-dependent manner. In breast cancer, we demonstrated that it dampens the activation of the EGF pathway. However, little is known on the role of miR-223 during breast cancer onset and progression. miR-223 expression was decreased in breast cancer of luminal and HER2 subtypes and inversely correlated with patients' prognosis. In normal luminal mammary epithelial cells, miR-223 acted cell autonomously in the control of their growth and morphology in three-dimensional context. In the MMTV-Δ16HER2 transgenic mouse model, oncogene transformation resulted in a timely abrogation of miR-223 expression, likely due to activation of E2F1, a known repressor of miR-223 transcription. Accordingly, treatment with CDK4/6 inhibitors, which eventually results in restraining E2F1 activity, restored miR-223 expression and miR-223 ablation induced luminal breast cancer resistance to CDK4/6 inhibition, both in vitro and in vivo. Notably, miR-223 expression was lost in microdissected ductal carcinoma in situ (DCIS) from patients with luminal and HER2-positive breast cancer. Altogether, these results identify downmodulation of miR-223 as an early step in luminal breast cancer onset and suggest that it could be used to identify aggressive DCIS and predict the response to targeted therapy. Significance: miR-223 may represent a predictive biomarker of response to CDK4/6 inhibitors and its loss could identify DCIS lesions that are likely to progress into invasive breast cancer.


19 June 2023 in Cancer Communications
Verified
Journal Article
Open access
ISIlenia Segatto
Ilenia Segatto
GVGian Luca Rampioni Vinciguerra
Gian Luca Rampioni Vinciguerra
IPIlenia Pellarin
Ilenia Pellarin
ADAlessandra Dall'ACqua
Alessandra Dall'ACqua
SBStefania Berton
Stefania Berton
Gustavo BaldassarreGustavo Baldassarre
Gustavo Baldassarre